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The kn&ii eue.cm of mlgic4~ronverliing eluyme in- 
bibitors io beatt More ood of ospirio io comoery totery 
tJi%ase om well eslsblished. In beorl foiboe. oRgioleositt- 
coowtliiy enzyme iobibitors are &acioos vomdiloton 
tbat exert sllomry e&cm oo oeorobomotol compmww 
mechmdams. h peiticular, tbrc4tpb reductmes in b&b rat& 
tensin U and nmq5inephtine. Heawdyoamic improvement is
6llin@ pressurea. which &-not appear to be sot&t to 
attenuation by pharmacologic tolerance or couoler- 
regolototy pheoomeoo. Tog&w with the bmtodyaamic 
chasgcs. other actions d these dtqs such as the reductiot~ 
in plasma norepitt@uine itaelt. &crease in vaaoprestin and 
tioatemtte, etdtancemea ef renal fun&n. rectiketion of 
eleaolyte mot, in pattialar tillI respst to potar- 
rinm. otegoesiom amI smiioot, or possibly eveo soppt&oo 
of onitytbmias-enable oot only aoteliomtion of symptoots 
(I-10) but evideotly o meaoi@id pmlo@iat c4 survival 
(11-13) m well. Tbmugb inbiMion of platelet aootegatien. 
aspirio has been showo to deawse mabidily OT mmialily ia 
almost evwy asp9ci of mnsly amY disease iltcMia 
bypass wgery (N-20). cmaequatty. kcatttc comnaly 
artcty disease is tk m&r cause of heart Ylnr (2132J. the 
prcwnsity for aMcimian of the hvo eondilians tieque& 
dictate.stheaeedfortbe&.sirede@atsc4betheoo@oteo- 
doawliog eozyltm bthiior sod ospbio eveo utoo$t tbe 
respcetive pv otecbooisttts m reeipmeauy 
counteractive in one fuodametmd respect. w- 
convertino aqme,inhiMas stim&4e pmdlpezanma syn- 




buther vasodilaw suppat by attgmeotiop rodttctioo of 
pmstqlandina. In contrast, qdrin inhibits pmsta&tdbt 
synthesis. and its intaded adion in mmnary artery disease 
is achieved tbtw+b bkwkode of the cnz~1114 c~dcax~em~ 
(24. Acemdindr,toinvertigarethedloicalnlevPncedthis 
tbeoatic dicbotooty using B mrdomiad, double-blind, 
crossover. plaabe.moauUedpmtocoJ io patients wiUtbwt 
faihnr, this study was uudutak= to delineate the kmcdy- 
uxl HALL ET AL 
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namic etkts of the an&ten&converting enzyme inhibitor 
enalapril when @en b&m aspkin, wocomimndy with 
aspirin sod the day after aspirin. 
Study pslients. The study (goup consisted cd ;6 plimts 
with chmnic. stable but severe hean Wilurz. There were 16 
men and 2 women 38 to 15 years old (average 60.2). All bad 
WC vi doe to-comoary artery disease is IO patients, did 
cardiomyopathy in 6 and hypertensive heart disease in 2. 
Mean ejection fmctio was 23.9% (InoSe 16% to 4c%). 
Awage mea pulmonary alay ptwsum at bwline was 
34.9 mm q (range 21 to 50). 
All patients bad beeo hospitalkd in fluid balance with no 
changs in weight for +4 days before the study. They wrc 
following a mtabolicatly stwdadized diet nod wem &en 
dose of-koacmide L% 
tbkidc) that wn? bcpt constant tbmlyhout the study. ND 
other vasmctive drgs were given, and tberc had been po 
exposole to arpirin a other IloMteruid rm&iirlmIrat~ 
drags for z2 weeks. The average serum scdiom ccncetiicm 
was 133 mmoLliter (moge 126 to 143). Only ooe pier6 was 
fmotdy byponatremic at a crmceetmtion of 126 mm&liter. 
Eemo@omle memuremeas. On the day before :‘re 
study. a semi-lloatiry, balbon-tippal catl.etw was p&i- 
tkmed io tbe polmonary artery fw determinations of ii&t 
atrial passme (RAP), polmooary artery presrwe (PAP) sod 
cardis output (CO) witb the tbermodilotioo tecbniqoe. 
Cardiac output measurements were cdnained in triplicate. A 
pmcwdii electmcardioysphic @4X) lead wzn oscd for 
rrmrding heart rate, sod systemic artuial pressore was 
obtaioed by electronic integmtioo. Mean systolic srlmisl 
prrssore (MAPj v/as calculated as diilii pmsswe plus ale 
tmra of tile pulse press”re. Systcndc vsscubx resixaocz 
(SVR) and total pulmonary resistaoce (TPR) werr exprrssed 
as dynersco-’ and catculated as SVR = 80 x (MAP - 
RAPXCl aml Till = 80 x PAP/CO. respect;vely. 
StwJy pMhuat. On Ibe nut 3 mmsecwive days. akr P 
ii&t brakfast at 130 AM, hemcdynamic mea.sotemeots 
titxe carried out at Io:OU AM (baaclioe). The drugs were thm 
aivm and the meawremeots repeated after I, 2 and 4 h. 
Hacebo,. eoalapil (IO m@ and aspirin (350 ms) were gtveo 
that yielded wmuwioon: fa exnmple.; with 
placebo #iveo on day I, double&&o on day 2 and 
eo@il plus aspirin on day 3 or double-placebo on day I, 
snalaplil plus aspirin on day 2 and eoataprit plur placebo on 
da), 3, 20 tbat for nine patieslts the day of coatapril alate 
warred befon they received aspirin and for nine p~tteots 
the day oftreatment with u?slspril occoned after aspirin was 
given. 
htlstlde Stadalcd M&IS isbnsedonchnq.a 
ineunad 4 h after the respectivr medications. The data were 
analyzed with a repeated aoalyis of variaaec. robjected to 
multiple compaisoo accotdii to the Friedmao teat. Di&r- 
ewes in the diuributloo of respollsiva!ess in the iodlvldual 
treatment gn?upr mre compared by the chi-square statistic. 
AlldatanreexprrssednsmcanvalueatSEM.Chsygwere 
~osidered to be statistically signilkant at the p < 0.M kvei. 
Remtlb 
mmlw.. The bcmadyoamic values reuxdul at 
4 h nfter admioisw&o of placebo I& the respeaive drug 
~~arc~lsycdio~~I.Tbcrrmrrmriaiecant 
chsnttes in mesa Ii& Mint pressure but P teodeocy to most 
fawable vatucs was seen after cordapril before aspEn. 
Meal pulmonary artuy pressore sbmved a teodency to 
increase with placebo (fmm 33.8 z 1.8 to 35.1 * I.7 mm I+@ 
dutio.9 the 4.b study period. Wttb coal@ befme sspirbi, 
there was a clearly dcrxcasiiry tmdcocy (from 34.6 + 3.0 at 
bas&te to 29.8 l 1.6 mm HP). On the dayr danb&l plus 
?&bl~IldEUd@~@io.thetendeilCylolkCBMd 
volucr~s~ln~~theRdUCtiDll~mnsmalkr~ 
32.6* 1.6atlaselb~to30.6+ 1.6mmHpandtktm36.1 = 2.3 
m tadinc m 33.4 + 0.8 mm Ii& 
left wotricular filling pressore was reduced sigotfkantly 
with etullrpril befme aspirin (Ran XI f 2.0 to 20.4 t 
1.6~Hg,p<O.M).Withplrcbo,~wrra~ 
increase (Itom 23.ll.f 4.1 vs. 24.1 f 1.3 mm Hg): witb 
eilplepil pbu aspb& (Mf of thmc patients hd alMy 
received etmlapril alooc), fmm a low baselIne tbue was a 
di&t incresse (fmm 21.3 f I.2 m 22.0 + I.2 mm Hg): with 
eoatapril after aspirin, from the l@hest basetiae there was 
~~~~otiallymdmt1%.~24.6~ 1.4(024.3+ I.OmmHg). 
With comlapil before as++. there ww P dear, but not 
si6xdkaot, decrease in toeat arteriat blmd ogre (fmm 
96.7 2 3.0 m90.6 * 4.0 mm Hg). Wiih placebo tk WBI no 
~ (94.2 k 3.0 vs. 94.8 f 2.1 mm Hg; with a&ptU with 
m atIer asplrbt, tktc were ~seotlrdty no &ut@s (from 
95.6 t 3.1 to 95.9 k 2.9 mm IQ and from 97.2 * 4.7 to 
97.8 * 4.8 mm Iis, rwec.tively) but both v&es taded to 
bcbi&ertbaoafter&cebo. 
Catdiac ootpot was sii biSber witb +*I 
before a6pirio @ C 0.05) by virtue d its teiy mutamed 
at the same level (4.1 t 0.7 “I. 4.1 + 0.6 liten/mio). 
In cootrat, with the t&e c4b.x &neos, over the 4-b 
period tbea% was a markdly deaeaslog tendency tplnceba 
4.1 i: 0.9 vs. 3.6 f. 1.0: malapril plus aspirin 4.0 f 1.0 vs. 
3.6 * 0.9; eoalapril after as$rin, from the lowrt baseline, 
3.8 + 0.9 vs. 3.5 + 1.0 liters/min. 
As canpad with the other regimens, total pulmonary 
nzststarce was lowered only by enalopril befcce @in (from 
714.8 t %A lo 694.1 t 58.8 dyneswm-‘, 9 < 0.92). Witb 
thethmeotherregimens,therewarakwdencym 
increased values (placebo 719.8 * 64.4 vs. 838.5 * 71.1 
dyoe.sw.m-‘:enala@lpriIplunaspirin7W.8 + MI.1 vs. 154.1 f 
76.5 dyussci&; enalapd after aspirin. from the biics~ 
bwline,~.4~69.5vs.810.4rt80.7dvn~scm~5.Inrhe 
tvm latter 6mup+ the incaare was I& tban with placebo 
because of tbe tendency to dewwed mean pulmonary 
Ntzry pxes*uIF. 
Similady, as compvsd with the other regimens. systemic 
vascular E&&XC was lowered only by endapril before 
aspirin (fmm 1.822.6 f 92.1 vs_ 1.642.7 f 68.0 dyneswm-‘. 
p<a~).).IhetbreeMber~nr,mertfielh~, 
&a. there was a dearly increasin6 tendency (placebo 
1.7XI.O f 74.9 vs. 1.993.7 f %.3 dyneswm-‘; mrdapiil 
pl6a &tin 186.1 k 87.4 vs. 2.060.7 f 95.4 dynearm+: 
a&pril after aspirin. fmm the &best klinc. L913.8 f 
129.0 vs. 2J19.8 I 175 dyneswan-3. 
ThchcartrateincheplPabogoup,abouto~thirdof 
whom bad previously rccetved endapril with or without 
qirin w both, remaid nearly idmticd (X9.4 2 11.3 vs. 
89.S t 8.4 Lmtdmin). With endapril before srp;tin no 
plticnt had pwimuly received coalapril and the bi&.st 
baseline value ~6s seen: altbougb the reduction was nat 
ri#lcant there w1s a deuly dearasing tendency (from 
94.8 t 9.1 VS. 89.8 = 5.5 beatrlmin). Wtth matqrtl plus 
rm@in. hdf of the patients bad abrady received ennlapril 
and, from a lower barcline. there was a ri6ai6c~t deuea~ 
f.fmm90.0e 10.6682.5~5.1beatslmin,9<0.~.with 
aIal&wil &r &in. all f#ltients had 8bEady received 
adapril and fmm the lomst baccline, there w a tiutber 
dcfM& (frra 82.6 f 10.6 to 76.6 f 6.9 beat&in). 
tndtvtt rapoms. To delineate individual reoprmsive- 
ness. we perfmrnrd a cbi-sqvme analysis of the chawges 
elicited in systemic vascular resiwrx by lbc rapective 
darn wakens GE. 3). A favor&? -se. deaimmted 
as J3 &crease i. ~yotemie vaseul~r resist&e of 
2306 dynenocm-5, was observed in I (6%) of I8 patients 
receiving placebo. 6 (fZ%) of 9 patients receiving matapril 
before awirtn and in 2 tll%I of I6 Daticnts receivine 
endapril &us aspbin. Tbek&ences inUle pmkabiltty d 
responding fworably to a regbncn of en&p16 before apt- 
rin. as compwd with donblsplacebo, and with adapril 
phu aspilin were siw (p < O.cnll and p < 0.01. 
respectively). 
kmhumml m In selected patients on all 3 
days afthe study. peumlnrmwa prmiks from blond drawn 
1 bowline and at 4 h rhmKd cvnsiaant and ccmoamblo 
incnaes in plasma rain acttvky of up m lC0% Ad do 
cMsesinmx+epbrineofXJ%to3Q%&erenalapril 
tbempy with or without aspbin but 6ot after double-placebo. 
hart tail&. a&a&conrcrti~ en&e inhibition with 
endamil siven t&a skin led to tbe anti&&d beneticial 
dlecis. A; corn-d itb place!, there w& P si&eent 
decrease in systemic vascdar rcastaw of 353.1 dyness 
cm-‘. Addiliondiy. lba’c wae s&nikam decreases in MI 
well as P dgnir;;ntl 0”tp”t:MemI ancrial 
but nc4 This u&e of hem&- 
zyme inhibitors, attriiutile to both a reduction in concen. 
trations of !he vawconstrictors angiotcnnn II and 
nwepinqbrinc and m increase in vasodilating proat~&~ 
dins (4,6,9,10,26,27,M), has rendered thex agcntr alnollg 
the most useful for treatment of heart tkiluw. 
Akuatedektswithoraftere+4~I0.Onthedayof 
treatment with enalapril plus Plpirin, as well as on the day of 
enalapril heatmerit after aspirin. thxe were no sigttificant 
ctkts wm9avJ with values with placebo on any of the 
tatter variables. Systemic vascular restatatxe actually in- 
creased. Jo that at the time aftbe anticipated maxbnal actton 
r: eualaprii when pjven with or the day after a&in. the 
respective Values were 67.0 and 126.1 dynessun-5 biia 
than Values with placebo and 418.1 and 477.2 dyncrscm-5 
hiier than vahtes alter enalapril befon aspirin. Accmd- 
ingly, as aswsed by c&square analysis, the likelihood of 
dfecting a mcani@.d nxtuc.tion in systemic vascular resis 
tame (arbhdy designated as a3KI dynesscm-‘1 was 
M&art&A pi~~re’st 9S.9 and 97.8~mm IQ also 
tated to be higher with ennlaprtl 8tven with w after aspirin, 
Irspectively. than after &c&lo (94.8 mm He). The clear 
tendency ta hi&r values Bm bah systemic vawdar nir- 
tance and blood ptw.ure stil! pntid at the baseline 
meastranettts On the FcdWiog dab. Cafdiac out@ at 3.6 
acd3.5litera/mittwitbett&ptilgiwtwithaaiteraspbin, 
(3.6 lbmhitn). artery prersurs t&&d to 
decrease (4.5 and I.7 mm t& reapeetively). The faihux of 
enaapril to eltit any sigaant etkct must be attrii to 
inhibition of pmrtaglandin synthesis by aspi& 
RlsLsldarm. The predominant hcmotlyttamic &ect d 
ikpaiients lnihis study, de- dtketfectsofpspirin 
may hwebeeofscitttated becaux,allhad marked cbudatcq 
daawmmt and, in par&l with the deBee of heart Pailulure 
itu prostttelattdjtts is stimulated (31-341. Comxqttmtt. the 
rcde dpmsta&ndiw in the cinadaw lkatte0aaf.i~ ofbeat 
imtnwement, the skll but co&tent de&tents in the 4-b 
and subseqwtd bwline valttes on tlte nrxt day suhgcst that 
the inhibitii of pnx.taSlandin synthgis by ewtt the rsl& 
tiVe1y smnu do%! Of wphin used in thta snldy Cal Itberate P 
ilent not only-to cause defauit.oF tat wen to override the 
systemic vasndilnti3n of ennlapril. 
In 9r&t~Iy repotted sh&s in pmiettts with heart 
tbiltue. the use c&m synthesis itdtii has also 
ml puhnomy arkry pnssurs and a-d&are in cludii 
o~tpot. p~Ii~olady in hypooatremic pxiims (26). and in at 
least Iwo instances to attenuate Ihe vandilator action of 
km~term adminisiration of captopril 127). 
Pharmacologic inhibition or cydaoxygenase by noo- 
steroid ami-inflnmmnwry drugs may have Iiuk or no effect 
in radium-replete, nomwtensivc subjects other than M 
evaoescent inaeasc in pmipheral resistance and artoial 
peswre and a small dcercasz in cardiac output after inba- 
venoos administrarion (3% However. iodomethacio pre- 
lrcrdmeot in mmwl volonkers sod labxatory animals in- 
the i~mediti~hypoleosive and p&ndol 
f35M& Moreover, concurrent lrealmnr with pmstaglaodin 
synthesis inhibiton such IIS aspkin or indomeihcin has 
been showo to attenoate the hypncnsive eIfens of bets- 
adrm~rgic blocking agems (41-44). diunk drugs (4&4I, 
45-47. hydraltine ML pmzasin (49) and captwil (2% 
25.X1-32). The cornmoo denomkm~~ of all of these intmac- 
lions is BP. increase in systemic vascular resistance. 
&pirin daac. Akhough maoy of the swdics cited in Ihe 
precediy section used very high doses of pMaglandm 
syntieais inhibitors. up to 2,4W mg of aspirin a d 400 mg of 
indometkacka daily. ill lens1 in the pltkols with z&axed 
hevt r* ia this study. vnsoeonrrrictioll w doeunrnti 
at a relatively low, 33omg dose of aspkin. we chose * 
standard (oppmximately Sqaio) 3SSmg do5t of aspirin as a 
compmmiae baarren lhal used in major coronary atwy 
disease mortality and rcinfarctkm st~xlics MII b I,OW mgl 




temclion may noI have been spci6caUy addmssed earlier 
baaox of hs ability Io dude d*ceIion in Ihe everyday 
haoaticms oft&&ii variables. WC did mu dwrw SY~R 
pa&k to and evco mod& exceeding that dthe placebo 
groop.lopmctice,adelioqurmre.qcmsecookIessilybe 
ovulooked especially if bwmeot is mollimrrd only with 
routine me asuremm~1 d blood pressure. becauac in an 
individual @ierd ml eXMCaed at a specified dmt wit&a the 
codmes of a dnceboumumlled hmwdyoamic soidy my 
aGo an olTsen& or the substantial iocrease in systemic 
vascular rcs~~~ce sod decrease in cardiac output that were 
otherwise consisterdly seen in tbe p&ho phase Anin& !!r 
coarse of the &tively h-q 14-h) observation period. We 
assume that this diumal panem relkns, in additii to the 
ard~ioos scbeduk with re.psslcd measwemeots and the ab- 
aence of a lunch @ad. primarily the diiian d post 
smptive vasodilation aflr bawkfast that is considered to 
persist forahoot3lo6hfS).Y)a~m~~~~o~ tinrrevert 
to control values. 
Eslablishine soil&k ccmomiwos bssed oo available 
pohhsbed d&is a fmmklabl~codcaw Lease IIIDSJ stud- 
ies or the :iiculatay &&IS ofenalapil ehber do not have a 
pkcehc controi phase. do not report acute bemodynamic 
changes or indicate ooly “p&C’ chaoger sekcted at will 
fmm measoremenls rangiog anywhere horn I 10 12 h after 
drug adminiwa6on with litrk or no indiislion of the lhnc of 
day-at which lhe swdies were performed or the pmximily 10 
meal ingestion. WC would bave preferred IO avoid the &ects 
d eating and other circumsmoeer ~spehlc of altmino kcnc 
dynamics. However. fa stodieo ci more than the shorten 
domtioo. when designing a plan with soy resemblance to 
customary everyday life. it is dit6coh to choose a time tkat 
does oat conflict with eitker waxing or w&g of some 
exlrhnic infiueoce. Nevnthekss. ose of the placebo comrd 
pb~re ~0ed ~olditiom ~~auy did r0r rll WS. 
-. . 
Ms. which is tbc pc&omwa regulamr of v&s t&r 
Lforeaqdrin. _ 
. . 
A sencrally dcsbr& dftct of angintensi~c0ovatiq 
e-c inkibitioo is slavif of the heall rz.%, n&b has 
been rewted faqomtly but not ooiwrs& (6.79). In Chese 
paieots, there was a sigokicant and. apparently. decremm 
ml shxving of the heart M rrom the hiist bus&w values 
whom had alr& received enalapril. Here. as wll. the 
most p&&k uplaaatioo for the hearat* Aowku is that 
iialsonprroentsunsltaednoponsivumstoihedr.:rurcefo 
llca@ncphrine. llle dccrewz io wrepincpfirinc, too, ap 
pepreddea.meoIaaodwysimilarto~tofthebc’atra(e 
whh the highest bmelinc vahle8 in patients with no pwioos 
expoaue to enalquil aml the louwt in the goup with 
to&&l &er arpbin. Tc+etktr whh tke increase in plasma 
r&o a&icy, uollsrmatron is provided that aogiotmsin- 
ccmwting enzyme bddbitkm. end presumably all of its 
pmsteglsndin independent biologic legacy, bed been 
ecbieved on all three regimens regerdless of the bemody- 
nantic cbsnges incurred. Analogously. even though tbe 
sntihgpertettsive elfect of beta-adrenergic blocking agents 
can be attenuated by concomitant use of nonstemid ami- 
balmatory drugs,.thc heart ratc-dowing effut is meirr 
teined (39,43,44); tbet is, cm&c bete.ed~-cnergie r ccpcor 
funaien remains intset and responsive to bets blockade. 
Otba odeniW dnrv ar&ms. Finallv, based on this 
short+& hemodynamic study, we cannot comment on 
other aspects of pmstaglendilt synthesis intMion, such 85 
the adverse bdluencc on renal funaion or interference with 
mneurreet diuretic t!~unpy. e c~reerstene of meet heert 
$ilure regimens. Huwever, potential opportunities for eddi- 
tiottsl itttemaions to imfmse surreptitious burdens on the 
circttlati~l during lot&tentt ueamtetu sx hotb reslistic nnd 
““merats (57-60). 
ahlcal ie@cntlons. In patients with xvere heert fail- 
ure. mnmmitent use of aspirin could compromise the ben- 
e&M ections of engimensin-conveniy enzyme inhibitas. 
putieulerly MI symptoms and survival. to whatever extent 
there ztions sre explicilly dependent on lhe hemodynsmic 
improvement rendeted by reduction in systetnk vascular 
resistance asd not on adjunct& effeas aeh as arrhythmia 
supparsionaothersctionsobtaioedbydin6nishcdmnccn- 
hations of engioten.sb~ 11. norepinephrine, v~ssin or 
eldatemne. Coeceitily, the use ofespirin mey be r&ted 
to scverel mnspieuats findings in teeently published re 
ports. For example, in tt plsceho-eontrclkd study dettala- 
pril in patients with heart failure atlet myocatdigl infsraion. 
tnstty or most of whom wete probably takbtg aspirin, them 
wee no effea on cardiopulmonary exercise perfommncc 
(61). In the >6.006 patients with myocerdiel infarction in the 
CONSENSUS U study. ell reportedly receiving eepirin. 
matelily in those treated with en&d wes the seme es in 
those given placebo (62). In two additiatal major morbid 
event studies, there was tmtsbiy greater risk izduaion with 
enelapiil in patients with nonischemic hean failure then in 
tboes with iecbemic heart diseerc (12,13). In tbe SOLVD 
study wmperbts! cnelepril with pleeebo, about 70% OF the 
patients bad iscbemie beert diseese end one third were 
reputed to have ban receiving aspirin: their risk redunion 
was less than hnlfoflhrd in p&ttts with heart failure due to 
aher causes and, because the incidence ofsudden death wss 
not lowered, mortelity in most likely ettriiteble to was.- 
ingafibeertfeibee. &trccemly, intbeoml p~scemtiond 
the detetium Ibe subgroup analysis. the outcome ofSOLVD 
pstiettts n?ceivit!g aspirin was shown to be rignbkently less 
bvomble (63). In the V-Hem II study compsring enslapril 
with the combination of hydralazine snd isosotbide dhtitmte, 
about halfofthepatkttts hadwm”uyartevdiseascbutthc 
numbu tekiw espinn wns tu.t specitkd. In-ttmt wudy, too, 
in patients withoet coronary ancry disease there wes e trend 
toward e preferentiel benefieitd e&t at mortelity in which 
lhtse tskii enaiapril famd better then those with hydrala- 
zinc and isosorbide dinitmtc. Ovcrsll, there wee no differ- 
ence in mortality tiom pump feilure betw6zn the two drug 
regimens, and the significantly better outcome in the enele- 
prilgroupwasdueevclurivelytoaRduetionin suddendeath 
(13). Here, tbs question tires whether it could be possible 
that, in the tmtientr with comnllly erterv diseese. wodila- 
&with eiiher en ar&tensi~&nverU~ enzy& inhibitor 
or with hydmlariE plus isoeorbide dinivpte wee equally 
s&ted by aspirin, kadbtg to IM change in bemt tXure 
deaths. 
Conrhsi~mn Our results indiime that cnalapril wo*s 
better when given witbout aspirin. Aecordi~ly, to txovi& 
optimally reliable treatment with an@ensln&wii~ en- 
zyme inhiiimrs for pslicnls with 8evere hena failure eed 
eoronery ertery disease, the use of methods of platelet 
inhibition that respect the ittt&ty of pmst&dbt metab- 
olism msy be required. 

